146 related articles for article (PubMed ID: 31735774)
1. Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice.
Aini K; Fukuda D; Tanaka K; Higashikuni Y; Hirata Y; Yagi S; Kusunose K; Yamada H; Soeki T; Sata M
Int Heart J; 2019 Nov; 60(6):1421-1429. PubMed ID: 31735774
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
[TBL] [Abstract][Full Text] [Related]
3. Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice.
Ganbaatar B; Fukuda D; Salim HM; Nishimoto S; Tanaka K; Higashikuni Y; Hirata Y; Yagi S; Soeki T; Sata M
Atherosclerosis; 2018 Aug; 275():124-132. PubMed ID: 29902700
[TBL] [Abstract][Full Text] [Related]
4. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
Terasaki M; Nagashima M; Nohtomi K; Kohashi K; Tomoyasu M; Sinmura K; Nogi Y; Katayama Y; Sato K; Itoh F; Watanabe T; Hirano T
PLoS One; 2013; 8(8):e70933. PubMed ID: 23967137
[TBL] [Abstract][Full Text] [Related]
5. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2017 Sep; 96-98():19-25. PubMed ID: 28347868
[TBL] [Abstract][Full Text] [Related]
6. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
[TBL] [Abstract][Full Text] [Related]
7. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice.
Lu J; Xiang G; Liu M; Mei W; Xiang L; Dong J
Atherosclerosis; 2015 Dec; 243(2):438-48. PubMed ID: 26520898
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of S1P Receptor 2 Attenuates Endothelial Dysfunction and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice.
Ganbaatar B; Fukuda D; Shinohara M; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
J Atheroscler Thromb; 2021 Jun; 28(6):630-642. PubMed ID: 32879149
[TBL] [Abstract][Full Text] [Related]
9. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
Gaspari T; Liu H; Welungoda I; Hu Y; Widdop RE; Knudsen LB; Simpson RW; Dear AE
Diab Vasc Dis Res; 2011 Apr; 8(2):117-24. PubMed ID: 21562063
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
[TBL] [Abstract][Full Text] [Related]
11. Supplementation of cyanidin-3-O-β-glucoside promotes endothelial repair and prevents enhanced atherogenesis in diabetic apolipoprotein E-deficient mice.
Zhang Y; Wang X; Wang Y; Liu Y; Xia M
J Nutr; 2013 Aug; 143(8):1248-53. PubMed ID: 23761653
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism.
Furukawa N; Koitabashi N; Matsui H; Sunaga H; Umbarawan Y; Syamsunarno MRAA; Yamaguchi A; Obokata M; Hanaoka H; Yokoyama T; Kurabayashi M
Heart Vessels; 2021 Jan; 36(1):136-146. PubMed ID: 33073318
[TBL] [Abstract][Full Text] [Related]
13. Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction.
Gao P; Li L; Wei X; Wang M; Hong Y; Wu H; Shen Y; Ma T; Wei X; Zhang Q; Fang X; Wang L; Yan Z; Du GH; Zheng H; Yang G; Liu D; Zhu Z
Hypertension; 2020 Jan; 75(1):150-162. PubMed ID: 31735085
[TBL] [Abstract][Full Text] [Related]
14. Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice.
Rahadian A; Fukuda D; Salim HM; Yagi S; Kusunose K; Yamada H; Soeki T; Sata M
J Atheroscler Thromb; 2020 Nov; 27(11):1141-1151. PubMed ID: 32101837
[TBL] [Abstract][Full Text] [Related]
15. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Zeng Y; Li C; Guan M; Zheng Z; Li J; Xu W; Wang L; He F; Xue Y
Cardiovasc Diabetol; 2014 Feb; 13():32. PubMed ID: 24490809
[TBL] [Abstract][Full Text] [Related]
16. Potential mitigating impact of a dipeptidyl peptidase-IV inhibitor, vildagliptin, on oxazolone-induced ulcerative colitis: Targeting the role of PI3K/AKT/mTOR and AMPK/Nrf2 signaling pathways.
Awad MM; El-Gohary RM; Ibrahim S; Abdel Ghafar MT; Farghal EE; Aboalsoud A; El-Shaer RAA
Int Immunopharmacol; 2024 May; 133():112110. PubMed ID: 38652960
[TBL] [Abstract][Full Text] [Related]
17. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice.
Lu Z; Zhang X; Li Y; Jin J; Huang Y
J Endocrinol; 2013 Jan; 216(1):61-71. PubMed ID: 23060524
[TBL] [Abstract][Full Text] [Related]
18. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.
Terasaki M; Nagashima M; Watanabe T; Nohtomi K; Mori Y; Miyazaki A; Hirano T
Metabolism; 2012 Jul; 61(7):974-7. PubMed ID: 22225957
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Ta NN; Schuyler CA; Li Y; Lopes-Virella MF; Huang Y
J Cardiovasc Pharmacol; 2011 Aug; 58(2):157-66. PubMed ID: 21558879
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.
Gaspari T; Spizzo I; Liu H; Hu Y; Simpson RW; Widdop RE; Dear AE
Diab Vasc Dis Res; 2018 Jan; 15(1):64-73. PubMed ID: 28976221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
